Inmed Pharmaceuticals Inc (INM) Institutional Ownership & 13F Filings (Q2 2026)

INM ranks #8385 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

20 institutions disclose a position in INM, but none treat it as a major bet — even Squadron Capital Management LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

Sabby Management, LLC has trimmed its INM position for two straight quarters, cutting it by $144.0K while still holding $69.7K.

INM is up 2.3% today, and institutions have been net buyers of $4.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

INM reported a net loss of $8.5M over the trailing twelve months.

• Not yet profitable — net loss of $8.5M over the trailing twelve months
• Revenue declined 6.7% year over year
• Net income declined year over year, from -$8.3M to -$8.5M
• Operating cash flow was negative, using $7.8M in cash
• Current ratio of 6.99x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.16x equity — within a conventional range